SUZHOU, China, Jan. 20, 2020 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections.
TenNor publishes article on TNP-2092 PO Potential Application in the Treatment of Gastrointestinal and Liver Disorders in ACS Infectious Disease. Please read the article through this link：https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.9b00374
CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. In addition, 223,900 cases of Clostridioides difficile occurred in 2017 and at least 12,800 people died. The report lists 18 antibiotic-resistant bacteria and fungi into three categories based on level of concern to human health—urgent, serious, and concerning: Urgent Threats Carbapenem-resistant Acinetobacter Candida auris Clostridioides difficile Carbapenem-resistant Enterobacteriaceae Drug-resistant Neisseria gonorrhoeae Serious Threats Drug-resistant Campylobacter Drug-resistant Candida ESBL-producing Enterobacteriaceae Vancomycin-resistant Enterococci (VRE) Multidrug-resistant Pseudomonas aeruginosa Drug-resistant nontyphoidal Salmonella Drug-resistant Salmonella serotype Typhi Drug-resistant Shigella Methicillin-resistant Staphylococcus aureus (MRSA) Drug-resistant Streptococcus pneumoniae Drug-resistant Tuberculosis Concerning Threats Erythromycin-Resistant Group A Streptococcus Clindamycin-resistant Group B Streptococcus Azole-resistant Aspergillus fumigatus Drug-resistant Mycoplasma genitalium Drug-resistant Bordetella pertussis